RecruitingPHASE2INTERVENTIONAL

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

This study is for people with a type of lung cancer that has spread to a few new spots, even though they are already receiving cancer treatment. Participants will be split into two groups. One group will continue with their current treatment plan, which might be a new medication, supportive care, or staying on their existing drug. The other group will receive a targeted radiation treatment called Stereotactic Ablative Radiotherapy (SABR) to these new spots, while also continuing their current cancer medication. The aim is to see if adding SABR can help control the cancer better without stopping their ongoing medication.

At a glance

Status

Recruiting

Phase

PHASE2

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Enrolment target

Start

05 Jan 2021

Estimated completion

01 Jul 2027

Lung Cancer Metastatic

What is this study about?

This study is looking into a specific situation called "oligo-progression" in people with non-small cell lung cancer that has spread.

Imagine your cancer treatment is generally working, but a few new small areas of cancer (between 1 and 5 spots) have started to grow or appear. This study wants to find out if adding a special type of radiation, called Stereotactic Ablative Radiotherapy (SABR), to these new spots can be helpful while you continue your current cancer medication. SABR is a very precise form of radiation that can deliver a high dose to a small area.

Currently, when this situation happens, doctors might choose several paths: starting a new cancer medication, focusing on supportive care, or sometimes continuing the current medication. This study will compare these standard approaches with using SABR on the new spots alongside your ongoing medication. The goal is to see if SABR can keep the cancer under control for longer and improve your outlook.

Key takeaways

This study compares a special radiation (SABR) with standard care for specific lung cancer situations.
It's for people with lung cancer that has spread to a few new, small spots while on existing treatment.
SABR is a very precise radiation aimed at these new spots.
Participants continue their current cancer medication if they receive SABR.
The study aims to see if SABR helps control the cancer for longer.
You will be randomly assigned to a treatment group.

Who may be eligible?

This study is looking for adults aged 18 or older who have been diagnosed with non-small cell lung cancer that has spread. You need to be currently on a cancer medication (like immunotherapy or targeted therapy) and have had between 1 and 5 new small spots of cancer appear, which your doctor thinks can be safely treated with SABR.

It's important that these new spots are outside of your brain and are not too large (less than 5cm). If you have cancer spread to your brain, you might still be able to join, but the brain lesions won't be counted in the 1 to 5 spots.

You won't be able to join if you are pregnant or breastfeeding, if any of your new cancer spots are larger than 5cm, or if you have certain medical conditions that would make radiation treatment unsafe.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have non-small cell lung cancer that has spread and are currently on treatment?
Have 1 to 5 new, small cancer spots appeared recently?
Are you pregnant or breastfeeding (if so, you can't join)?
Are any of your new cancer spots larger than 5cm (if so, you can't join)?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you will be randomly assigned to one of two groups, like flipping a coin. You won't get to choose which group you are in. One group will receive Stereotactic Ablative Radiotherapy (SABR) to their new cancer spots while continuing their current cancer medication. The other group will continue with their standard care plan, which could involve a different cancer medication, supportive care, or staying on their current treatment.

The specific visits and assessments will depend on which group you are in and what your doctor thinks is best. For example, if you receive SABR, you'll have specific appointments for that treatment. If you are in the standard care group, your appointments will follow your usual treatment schedule. The total duration of your participation will depend on your specific treatment plan and how your cancer responds.

Potential risks and benefits

Taking part in any clinical trial has potential benefits and risks. You might benefit from closer monitoring or from receiving a treatment (SABR) that isn't always part of standard care for this situation. However, SABR, like all medical treatments, carries risks such as potential side effects from radiation. The study aims to understand if the potential benefits outweigh these risks in this specific situation. It's important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Centre Hospitalier de l'Université de Montréal
Verified postcode
Montreal, Canada· Recruiting

Common questions

What is 'oligo-progression'?

It means your cancer is mostly stable, but a few new, small areas of cancer have started to grow or appear.

What is SABR?

SABR stands for Stereotactic Ablative Radiotherapy. It's a very precise type of radiation that targets small cancer spots with high doses.

Will I have to stop my current cancer medication?

No, if you are in the SABR group, you will continue your current cancer medication alongside the radiation treatment.

How many cancer spots can I have to be in the study?

You can have between 1 and 5 new cancer spots outside of your brain to be considered for the study.

Can I choose which treatment group I'm in?

No, participants are randomly assigned to one of the two treatment groups, like drawing lots.

How to find out more

Silvine Benth

silvine.benth.chum@ssss.gouv.qc.ca 514-890-8254 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.